Previous research has not been conclusive regarding the association between selenium (Se) and breast cancer. This study was conducted to clarify if there is an association between prediagnostic serum Se levels and breast cancer risk. A population based cohort, the Malm€ o Diet and Cancer Study, was used and linked with the Swedish cancer registry up to 31 December 2013. Our study included 1,186 women with breast cancer and an equal number of controls. Selenium levels were analysed from stored serum samples. The included individuals were divided into quartiles based on Se value and we compared breast cancer cases with controls using logistic regression yielding odds ratios (OR) with 95% confidence intervals. Serum Se was also analysed as a continuous variable regarding breast cancer risk. The analyses were adjusted for established risk factors and stratified on smoking status and body mass index (BMI). When comparing the highest Se quartile with the lowest, the adjusted OR for breast cancer was 0.98 (0.75-1.26). With selenium as a continuous variable the adjusted OR was 1.00 (1.00-1.01) per 10 ng/ml. When comparing the highest with the lowest Se quartile in women with BMI > 25 kg/m 2 the adjusted OR was 0.77 (0.53-1.14). We conclude that it is unlikely that prediagnostic serum selenium is overall associated with breast cancer risk and no modifying effect from BMI or smoking was seen.
Selenium has previously been studied and proposed to be protective from breast cancer but the evidence is not conclusive. [1] [2] [3] [4] [5] The micronutrient Se is integrated in selenoproteins, a group of proteins with a variety of biological functions ranging from thyroid deiodinases to immunoregulation. It has been suggested that several selenoproteins may be protective against cancer, e.g. glutathione peroxidases, selenoprotein p and thioredoxin reductase. All three have anti-oxidative functions and the latter is also believed to have regulatory functions of transcription, cell proliferation and apoptosis that are potential biological links. 2, 6, 7 Indeed, several studies have found epidemiologic evidence of selenium and an inverse risk of e.g. stomach-and hepatocellular cancer as well as risk of advanced prostate cancer, although a protective effect of Se-supplementation has been questioned for those cancers. 2, 5, [8] [9] [10] [11] In the 1990s several studies were performed regarding Se and breast cancer risk but they showed inconclusive results, with some reporting an inverse relationship and some not finding any association. [12] [13] [14] [15] [16] [17] [18] A review of these studies in 2007 showed no overall association with the risk of breast cancer. 1 However, expecting a rather modest effect, many of these studies might have had too few cases to get statistical power, the largest one including 434 cases. 17 Other previous limitations are that in many studies selenium was measured after the development of breast cancer, a fact that makes it difficult to exclude that the selenium status is affected by the disease or its treatment. 19, 20 A stronger design would be prospective studies to avoid this potential bias that breast cancer affects the Se levels. Another issue regards exposure assessment, where some studies used selenium intake as exposure and some measured selenium levels in plasma, erythrocytes or toenails. 12, 17, [21] [22] [23] Indeed, in a recent systematic review and meta-analysis by Babaknejad et al. (2014) including studies with selenium measured in blood/serum and toenails, an inverse association with breast cancer risk was only seen in relation to serum selenium. 4 However, another recent meta-1,186 breast cancer cases from a cohort with prospectively measured serum selenium values and data on established risk factors for breast cancer, making it by far the largest prospective study on the potential association between serum selenium and breast cancer risk. [1] [2] [3] 5 Some factors could possibly modify the effect Se levels may have on breast cancer. Se has been shown to be lower in smokers, proposed to be due to increased inflammatory response and decreased bioavailability. 25 Indeed, a stronger association between low Se and prostate cancer has been found among smokers. 26 BMI is a well-established risk factor for breast cancer in postmenopausal women and, as well, a high BMI seem to inversely correlate with Se levels. 27, 28 Thus making it important to study if BMI and smoking modify the relation between Se and breast cancer risk.
The aim of this study was to investigate the association between prediagnostic serum selenium levels and breast cancer risk. Additional aims were to explore if smoking and BMI modify this potential association.
Material and Methods

The Malm€ o Diet and Cancer Study (MDCS)
The MDCS is a population-based cohort in the city of Malm€ o, Sweden. Between the years of 1991 and 1996 every citizen of Malm€ o born between 1923 and 1950 were invited. A total of 28,098 individuals including 17,035 women were recruited, and 43% of eligible women participated in the study. Baseline examination included a questionnaire, measurements of height and weight and blood sample collection. All blood samples were stored at 2808C. 29 The present study was approved by the local ethical committee. DNR 2015/283.
The questionnaire contained potential and established risk factors for breast cancer. A woman was considered post-/ perimenopausal if her menstruations had stopped prior to baseline examinations or if she had undergone bilateral oophorectomy. In about 2% of the women neither of the above-mentioned information was available and in that case if the woman was 42 years old at baseline she was classified as post-/perimenopausal. Women who did not meet the criteria for being post-/perimenopausal were classified as premenopausal.
Matching and study population
Breast cancer cases were retrieved by record linkage with The Swedish Cancer Registry up to 31 December 2013. Prevalent breast cancer cases at baseline (n 5 576) were excluded and 1,186 women had been diagnosed after baseline examination, i.e. 1,186 incident cases.
The selection of controls was based on a previous study from MDCS on breast cancer and vitamin D including cases diagnosed up to 31 December 2006 (n 5 764) and an equal number of controls that were matched on time at inclusion, menopausal status and age with the method incidence density matching. 30 Due to the nature of incidence density matching, this resulted in 704 unique control individuals and out of them 694 remained free of breast cancer up until 31 December 2013. In order to get the same number of controls as the 1,186 cases in our present study, additional controls were selected from the cardiovascular (CV) cohort in the MDCS. This subcohort includes 3,531 randomly selected women that completed baseline examination. Of these, 2,615 were complete participants in MDCS without breast cancer up to 31 December 2013 and 492 of them were randomly selected, making it a total of 1,186 unique controls. The reason we choose to select controls from the CV cohort is because that population was planned for genotyping in a parallel study.
Laboratory analyses
Analyses of the saved serum were performed in a blinded fashion by ALS Scandinavia AB, Luleå, Sweden. Samples were analysed by using single element standards, traceable to NIST, on ICP-SFMS (Thermo Element 2). An amount of 0.15 ml serum was diluted to 10 ml with an alkaline solution containing 0.1% NH 3 and 0.005% EDTA/Triton-X. Reference material, Seronorm, was obtained from Sero AS, Norway (Lot 0608414) and was analysed along with the samples. CV for interbatch variation was 0.03 and limit of detection was 0.4 ng/ml. A total of 262 women had missing selenium data since they lacked a sufficient amount of stored serum.
Statistical methods
The cohort was divided into quartiles based on serum selenium. The quartiles were compared regarding factors potentially influencing breast cancer risk and/or serum selenium levels. The same comparison was made between cases and controls.
An unconditional logistic regression analysis was used to calculate OR and 95% confidence intervals for different quartiles as compared to the first. Using serum Se as a continuous variable, we calculated the OR associated with an increase in 10 ng/ml of Se in serum. Linear trends over quartiles were also calculated. The multivariate analysis included BMI, age What's new? Selenium, a micronutrient integrated in several proteins with anti-oxidative and possibly transcription and cell proliferation regulatory functions, has been suggested to be protective against breast cancer. The evidence, however, remains inconclusive. Here, the authors set to clarify if there is an association between pre-diagnostic serum selenium levels and breast cancer risk by studying 1,186 cases, making this study larger than all the previous prospective studies combined. The analyses were adjusted for established risk factors and stratified on smoking status and body mass index. The results do not support an overall association between prediagnostic serum selenium and breast cancer risk. at first childbirth, age at menarche, age at baseline, education, socioeconomic status, marriage, number of children, oophorectomy, menopausal status, hormone replacement therapy (HRT), use of oral contraceptives, alcohol consumption, year and time of year (spring, summer, autumn or winter) when the sample was collected. The analyses were also performed stratified for smoking habits (ex, current, never) and BMI (>25 kg/m 2 and 25 kg/m 2
). An interaction term was included in the analysis to investigate a potentially modifying effect by these factors. The same analyses were also performed in the early and late controls (up until or after 31 December 2006, respectively) to see that the association between Se and breast cancer was similar amongst the matched case-controls set and the one were controls were randomly selected. We also performed sensitivity analyses in the group of women who were both smokers and had BMI > 25 kg/m 2 as well as in never-smokers with BMI 25 kg/m 2 . Two other sensitivity analyses were also performed, one in the group of women with BMI > 30 kg/m 2 and one when excluding all cases who got breast cancer within two years from baseline examination. All p values were two-sided and a p value <0.05 was considered as statistically significant. Statistical analyses were performed with IBM SPSS v23.0.
Results
Premenopausal women and those in the age group 49 had lower selenium values. Serum Se was lower in current smokers and in those with BMI > 30 kg/m 2 . The serum samples collected during spring contained higher selenium values than those collected during other seasons. The women with missing selenium values were older, less educated, had higher BMI and were more likely to be post-/perimenopausal (Table 1) .
Cases were younger, more educated, had higher BMI and were more likely to be premenopausal at time of inclusion as well as to be using HRT or having used oral contraceptives compared to controls ( Table 2) . Cancer Epidemiology
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It was no overall association between serum selenium and breast cancer. This was seen both when comparing the quartiles and when selenium was analysed as a continuous variable (OR 1.00:1.00-1.01). Crude and adjusted analyses were similar (Table 3) .
When the data was stratified based on BMI we found no statistically significant associations between serum selenium and breast cancer risk in the different groups. When comparing the highest selenium quartile with the lowest amongst women with BMI 25 kg/m 2 , the adjusted OR was 1.18 (0.82-1.70, p for trend over quartiles 5 0.36) and amongst them with BMI > 25 kg/m 2 , the adjusted OR was 0.77 (0.53-1.14, p for trend over quartiles 5 0.12). The interaction analysis did not show a significant effect of BMI on this association (p 5 0.16) ( Table 3 and Fig. 1 ).
When the data was stratified on smoking we found no statistically significant association between serum selenium and breast cancer. When comparing the highest selenium quartile with the lowest the adjusted OR for never smokers was 0.96 (0.64-1.44), for current smokers 0.95 (0.55-1.65) and for ex-smokers 0.85 (0.51-1.41). However, the biggest differences were seen in quartile 3, the adjusted OR for never smokers was 0.86 (0.58-1.29), for current smokers 1.32 (0.79-2.20) and amongst ex-smokers 0.87 (0.51-1.49). The interaction analysis did not show a significant effect of smoking on the association (Table 4) .
When the data was stratified for the two different case-control sets, no statistically significant association between selenium and breast cancer was found. When comparing the highest selenium quartile with the lowest amongst cases diagnosed up to 31 December 2006 and the matched controls, the adjusted OR was 0.86 (0.61-1.21). The same analysis amongst cases diagnosed after 31 December 2006 and the randomized controls rendered an adjusted OR of 1.04 (0.62-1.74). The interaction analysis between the groups did not render any statistical significant p values in crude or unadjusted analysis (Supporting Information Table 1 ).
When excluding the women who got breast cancer within 2 years from baseline no statistically significant differences were seen. In the group current smokers with BMI > 25 kg/ m 
Discussion
Our results do not support an overall association between serum selenium and breast cancer risk. We did not find any evidence of a modifying effect from smoking or BMI, and a protective effect of selenium is not likely in any of those groups. This study has almost three times the number of breast cancer cases than the second largest comparable study with prospectively measured selenium and it has data on most established risk factors for breast cancer and the present study adds to the evidence that there is no association between Se and breast cancer risk. 17 The association between Se and breast cancer has been studied for a long period, though previous research has not been conclusive. Similar to our results, Hunter et al. (1990) and Moradi et al. (2009) found no significant association between Se levels and breast cancer. 17, 31 However, several studies, including Hardell et al. (1993) and Rejali et al. (2007) did find a significant association between low Se (in plasma and serum, respectively) and an increased risk of breast cancer. 12, 20 Two recent meta-analyses also suggest an association. 3, 4 However, both of these reports do include case-control designs with Se measured after breast cancer diagnosis. One meta-analysis also had very high weight for one of the included studies for unexplained reasons (79%) and included studies with different end-points making it difficult to interpret the result. 3 In a Cochrane systematic review Vinceti et al. (2014) used stricter inclusion criteria. Indeed, in that review with only prospective studies no association was found between selenium and breast cancer. The total number of breast cancer cases analysed in that report by Vinceti et al. is 985 and combined with our 1,186 cases it makes it unlikely that an overall association between prediagnostically measured Se and breast cancer exists. 5 A possible interpretation of previous studies that found an association between a low Se value and breast cancer is that Se was measured following diagnosis and low Se levels might be an effect of breast Adjusted for BMI, age at first childbirth, age at menarche, age at baseline, education, socioeconomic status, marriage, number of children, oophorectomy, hormone replacement therapy, use of oral contraceptives, alcohol consumption, smoking status, year and time of year sample was collected, menopausal status. 2 Adjusted for all factors above except BMI. One control was missing BMI data. cancer or its treatment. This is supported by several other reports, including a review from Ladas et al. (2003) on antioxidants and cancer therapy suggesting that both malignancy and related treatment lowers anti-oxidant levels, Se included. 32, 33 Still, selenium has in preclinical and animal studies shown to inhibit cancer growth. Several potential biological mechanisms have been suggested. According to a review by Davis et al. (2012) approximately half of the 25 characterized selenoproteins have antioxidant effects, direct or by transcription of other substances. 34 The selenoproteins glutathione peroxidase and thioredoxin reductase both play major roles in reducing the intracellular oxidative stress by reduction of hydrogen peroxide and thioredoxin respectively. Baliga et al. (2007) suggests that Se, through glutathione peroxidase-1, increases DNA stability either by prevention or repair of DNA damage in breast cancer cells. [34] [35] [36] It has been suggested that selenium might have more effect on advanced cancers than on localized tumours and studies in mice have found organic Se supplementation to reduce breast cancer metastasis. 26, 37 This is also supported by Harris et al. (2012) that found a significantly lower breast cancer mortality in Swedish women with higher Se intake. 21 There is also evidence supporting that genetic factors modify the cancer risk in regards to Se status, suggesting that it may be important to include such information.
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Regarding the use of Se as a supplement, the nutritional prevention of cancer trial (2002), found a nonsignificant higher incidence of breast cancer in the Se-supplemented group compared to placebo although it was very few cases (11 vs. 6) . 10 This and other supplementation trials have mainly focused on other types of cancers than breast cancer but a positive effect of Se supplementation has been seen in primary liver cancer and in those with low serum-Se regarding colorectal-, lung-and prostate cancer but a null result in the largest study so far and even an increased risk for skin cancer in one study. 9, 10, 38 The stratification on smoking and BMI did not show any statistically significant interaction. The biological mechanism that obese persons are more likely to be depleted of antioxidant enzymes, including the selenoprotein glutathione peroxidase and that such a depletion is suggested to affect antioxidant defence and breast carcinogenesis does not seem to have a real life effect. 39, 40 It should also be noted that BMI might be a confounding factor having an impact on both serum selenium and breast cancer risk. 27, 28 Previously, smoking has been identified as a source of confounding when studying selenium and cancer risk, as seen in for example, bladder cancer. 41 Although both the tobacco plant and cigarette smoke contains Se, it has been found to be lower in smokers. The mechanism behind it is not fully understood but the decrease is proposed to be due to increased inflammatory response and a decreased bioavailability as a result of increased Cadmium levels in serum. 25, 42 The fact that analyses were adjusted for both these possibly confounding factors should be considered as a strength of this study. A limitation in our study is that we measured the total amount of Se in serum and could therefore not specify the levels of the different chemical forms of Se that it consists of (e.g. glutathione peroxidase, selenoprotein p and inorganic Se). As Vinceti et al. (2015) pointed out this is a potential risk for exposure misclassification since these Se species can have different biological properties and do not necessarily correlate to the total Se. In the same article, the authors also found that the distribution of Se in different forms correlates with storage time and that total Se had a nonsignificant increase related to storage time. 15, 43 Our analyses were adjusted for year of baseline examination and as all laboratory analyses were performed within a short period, our analyses include an adjustment for storage time. In our study a single measurement of Se in serum was done, this method has been found to be adequate when ranking subjects and representative to long-term selenium intake, although the serum Se value represents short-term intake as well. 44, 45 The interbatch coefficient of variation on our Se analyses was 3.4% and thus strengthens our results reliability. A weakness of our study design is that we used two different types of selection criteria for our control group. Some are matched (n 5 694) and some are randomly selected (n 5 492). The differences between cases and controls are fully visualized in Table 1 and relevant factors are adjusted for in the analyses. We also performed logistic regression analysis when stratifying the data on the two time periods, the one with matched controls and the one with randomized controls to see if they were similar, as is visualized in Supporting Information Table 1 .
We do not believe that there are any differences between our control groups that have had any major impact on the results of our study. As mentioned above, genetics is another parameter to include in future studies. We used The Swedish Cancer Registry to select our cases, a database with a high validity and completeness. 46 The participation rate in the MDCS was 43%, however, previous analyses have shown that participants are similar to the overall background population regarding factors like socioeconomy, BMI and smoking. 29 Selenium levels in the study population may differ from other studies, but selenium levels are relatively low in Sweden, and if anything, this would be an advantage in studies on Se and cancer risk as it has been suggested that a potential association would only be seen in selenium-low areas. 11, 47 Selenium intake is positively correlated to serum-Se and is lower in populations where the Se content of the soil is low since the subsequent Se content of crops and vegetables is dependent on the soil. 45, 48 The Se intake is therefore lower in large parts of Europe, including Sweden, as compared to, for example, the United States. 49, 50 The reason that 262 women did not have sufficient amount of serum to analyse was because they were early cases and controls (Supporting Information Table 1 ) and their serum had been used in previous case/controls studies on breast cancer.
Above-mentioned knowledge makes Se and breast cancer an important area for further research, although an overall association between selenium status and breast cancer risk is not likely. Tumour characteristics and genetic data should be considered in future studies.
